Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVE: Colonic dysbiosis contributes to the development of colonic inflammation in ulcerative colitis (UC). Fecal microbial transplantation (FMT) is being proposed as a novel treatment for UC because it can eliminate dysbiosis; however, no prospective data exist. We initiated a pilot study to evaluate feasibility and safety of FMT in children with UC. METHODS: Ten children, 7 to 21 years of age, with mild-to-moderate UC (pediatric UC activity index [PUCAI] between 15 and 65) received freshly prepared fecal enemas daily for 5 days. Data on tolerability, adverse events, and disease activity were collected during FMT and weekly for 4 weeks after FMT. Clinical response was defined as decrease in PUCAI by >15, and decrease in PUCAI to <10 was considered clinical remission. RESULTS: No serious adverse events were noted. Mild (cramping, fullness, flatulence, bloating, diarrhea, and blood in stool) to moderate (fever) adverse events were self-limiting. One subject could not retain fecal enemas. Average tolerated enema volume by remaining 9 subjects was 165 mL/day. After FMT, 7 of the 9 (78%) subjects showed clinical response within 1 week, 6 of the 9 (67%) subjects maintained clinical response at 1 month, and 3 of the 9 (33%) subjects achieved clinical remission at 1 week after FMT. Median PUCAI significantly improved after FMT (P = 0.03) compared with the baseline. CONCLUSIONS: Fecal enemas were feasible and tolerated by children with UC. Adverse events were acceptable, self-limiting, and manageable by subjects. FMT indicated efficacy in the treatment of UC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These reports were followed by a number of small studies of FMT in children and adults with UC, CD, and pouchitis with mixed results.64–72”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [68]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 6×
“A recent study (7) evaluating the role of FMT in treating recurrent C difficile infection reported adverse events, which, similar to our study, were predominantly GI symptoms.”
BackgroundMethodResultInfluentialDysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713 · cited 1×
“The colonic microbiome in patients with UC has decreased richness and diversity (2,3) and is dysfunctional (4) (dysbiosis).”
BackgroundTurner, D., Otley, A. R., Mack, D., Hyams, J., de Bruijne, J., Uusoue, K., Walters, T. D., Zachos, M., Mamula, P., Beaton, D. E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.029 · Cited by 1,072 · cited 2×
“Therefore, clinical response was defined as a decrease in PUCAI by >15 points after FMT (17).”
BackgroundMethodTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 2×
“Donor exclusion criteria were guided by our IND, the American Association of Blood Bank Donor History Questionnaire version 1.1, and the recommendations from the American Gastroenterological Association (16).”
BackgroundInfluentialHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“Multiple studies have used various bowel sterilizing preparations (antibiotics and bowel cleanout) before FMT (19,20) to help donor microbiota establish in the new host.”
BackgroundKhoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 2×
“Recent evidence suggests that FMT, the infusion of fecal preparation from a healthy donor into the GI tract of a patient, is capable of altering the gut microbiome of the new host (6,7).”
BackgroundMethodGophna, U., Sommerfeld, K., Gophna, S., Doolittle, W. F., & Veldhuyzen van Zanten, S. J. O. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01004-06 · Cited by 550
Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases
Peterson, D. A., Frank, D. N., Pace, N. R., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.001 · Cited by 503 · cited 1×
“The colonic microbiome in patients with UC has decreased richness and diversity (2,3) and is dysfunctional (4) (dysbiosis).”
BackgroundTursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489 · cited 1×
“Probiotics, for example, VSL#3, have shown some usefulness in the treatment of UC (5); however, not all probiotic formulations contain the same species, their efficacy may be strain specific, and understanding of their mechanism of action in the complex gastrointestinal (GI) microbiome is lacking.”
BackgroundTreatment of Ulcerative Colitis Using Fecal Bacteriotherapy
Borody, T. J., Warren, E. F., Leis, S., Surace, R., & Ashman, O. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200307000-00012 · Cited by 388 · cited 3×
“As reported previously (10), because of the chronic process of colonic inflammation, multiple FMT sessions may be needed to see a clinical response in UC.”
BackgroundMethodPROSPECTIVE DIAGNOSIS OF SPINA BIFIDA
Brock, D. J. H., Scrimgeour, J. B., Chard, T., Leek, A. E., Kitau, M. J., & Leighton, P. C. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91459-2 · Cited by 361
Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease
Anderson, J. L., Edney, R. J., & Whelan, K. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05220.x · Cited by 313 · cited 2×
“A recent systematic review of case reports on the use of FMT in the management of inflammatory bowel diseases indicated that 76% of subjects experienced improvement in symptoms and 63% achieved clinical remission after FMT (9).”
BackgroundTreatment of ulcerative colitis by implantation of normal colonic flora
Bennet, J., & Brinkman, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91183-5 · Cited by 304 · cited 1×
“Since the first case report nearly 2 decades ago (8), FMT has been used sporadically to treat inflammatory bowel diseases (9), with claims of clinical (10) and endoscopic remission (11).”
BackgroundAlterations in the gut microbiome of children with severe ulcerative colitis
Michail, S., Durbin, M., Turner, D., Griffiths, A. M., Mack, D. R., Hyams, J., Leleiko, N., Kenche, H., Stolfi, A., & Wine, E. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22860 · Cited by 284 · cited 1×
“The colonic microbiome in patients with UC has decreased richness and diversity (2,3) and is dysfunctional (4) (dysbiosis).”
BackgroundDurable Alteration of the Colonic Microbiota by the Administration of Donor Fecal Flora
Grehan, M. J., Borody, T. J., Leis, S. M., Campbell, J., Mitchell, H., & Wettstein, A. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181e5d06b · Cited by 253 · cited 2×
“Multiple studies have used various bowel sterilizing preparations (antibiotics and bowel cleanout) before FMT (19,20) to help donor microbiota establish in the new host.”
BackgroundMethodA Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative Colitis
Turner, D., Seow, C. H., Greenberg, G. R., Griffiths, A. M., Silverberg, M. S., & Steinhart, A. H. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.024 · Cited by 190 · cited 11×
“Clinical remission was defined as decrease in PUCAI to 10.”
MethodInfluentialFecal Flora Reconstitution for Recurrent Clostridium difficile Infection: Results and Methodology
Rohlke, F., Surawicz, C. M., & Stollman, N. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181dadb10 · Cited by 165
Guo, B., Harstall, C., Louie, T., Veldhuyzen van Zanten, S., & Dieleman, L. A. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05033.x · Cited by 135 · cited 1×
“Although abundant data support the possible use of FMT in the treatment of recurrent Clostridium difficile infection with a success rate of nearly 90% (7,12,13), limited reports are available on its role in treating UC.”
BackgroundFecal Microbiota Transplantation
Borody, T. J., & Campbell, J. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.08.008 · Cited by 115 · cited 1×
“Since the first case report nearly 2 decades ago (8), FMT has been used sporadically to treat inflammatory bowel diseases (9), with claims of clinical (10) and endoscopic remission (11).”
BackgroundImpact of ulcerative colitis from patientsʼ and physiciansʼ perspectives
Rubin, D. T., Siegel, C. A., Kane, S. V., Binion, D. G., Panaccione, R., Dubinsky, M. C., Loftus, E. V., & Hopper, J. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20793 · Cited by 104 · cited 1×
“The psychological turmoil associated with UC appears to be profound in children, who seem less able than older patients to adapt and cope with their disease (14,15).”
BackgroundStruggling with recurrent Clostridium difficile infections: is donor faeces the solution?
van Nood, E., Speelman, P., Kuijper, E. J., & Keller, J. J. (2009) · Eurosurveillance · doi:10.2807/ese.14.34.19316-en · Cited by 99
Rubin, D. T., Dubinsky, M. C., Panaccione, R., Siegel, C. A., Binion, D. G., Kane, S. V., & Hopper, J. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0953-7 · Cited by 68 · cited 1×
“The psychological turmoil associated with UC appears to be profound in children, who seem less able than older patients to adapt and cope with their disease (14,15).”
BackgroundClostridium difficile— Beyond Antibiotics
Kyne, L. (2010) · New England Journal of Medicine · doi:10.1056/nejme0910055 · Cited by 48 · cited 1×
“We did this to limit the theoretical risk of sepsis from possible translocation of new bacteria through inflamed mucosa during FMT, although no such risk has been reported yet (7,21).”
BackgroundAngelberger, S., Lichtenberger, C., Gratzer, C., Papay, P., Primas, C., Eser, A., Mikulits, A., Dejaco, C., Novacek, G., Vogelsang, H., et al. (2012) · Journal of Crohn s and Colitis · doi:10.1016/s1873-9946(12)60393-6 · Cited by 11
Fecal transplantation in patients with moderately to severely chronic active ulcerative colitis (UC)
Angelberger, S., Lichtenberger, C., Gratzer, C., Papay, P., Primas, C., Eser, A., Mikulits, A., Dejaco, C., Novacek, G., Vogelsang, H., et al. (2012) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0032-1313841 · Cited by 6 · cited 1×
“Similar to our study, development of fever after FMT without signs of sepsis or positive blood culture has been reported in patients with UC (22).”
Result
Cited by
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Gut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
“difficile infection [32] and other GI conditions, although there is a growing interest in the use of several doses [35].”
BackgroundThe microbiome in early life: Implications for health outcomes
Tamburini, S., Shen, N., Wu, H. C., & Clemente, J. C. (2016) · Nature Medicine · doi:10.1038/nm.4142 · Cited by 1,213
The gut microbiota and inflammatory bowel disease
Matsuoka, K., & Kanai, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0454-4 · Cited by 804
“%) within 1 week [59].”
Metadata
- Authors
- Kunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S.
- Affiliations
- Spectrum Health (US)
- Michigan State University (US)
- Emory University (US)
- Corresponding author
- Kunde, Sachin
- Pham, Angela
- Crumb, Teri
- Duba, Meg
- Conrad, Harold
- Cloney, Deborah
- Venue
- Journal of Pediatric Gastroenterology and Nutrition
- Publisher
- Wiley
- Published
- 2013-06
- Volume
- 56
- Issue
- 6
- Pages
- 597-601
- ISSN
- 0277-2116 (ISSN-L)
- 1536-4801
- OpenAlex
- W2121245825
- Cited by
- 314
- References
- 26
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 8 · 2023: 14 · 2022: 14 · 2021: 17 · 2020: 26 · 2019: 26 · 2018: 23 · 2017: 40 · 2016: 34 · 2015: 38 · 2014: 42 · 2013: 16
- FWCI
- 28.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pediatric Gastroenterology and Nutrition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Surgery › Anorectal Disease Treatments and Outcomes
- Keywords
- fecal microbiota transplantation, ulcerative colitis, pediatric inflammatory bowel disease, colonic dysbiosis, clinical remission, safety and tolerability, adverse events, disease activity
- MeSH terms
- Administration, Rectal, Adolescent, Adult, Biological Therapy, Child, Colitis, Ulcerative, Family, Feasibility Studies, Feces, Female, Follow-Up Studies, Hospitals, Pediatric, Humans, Male, Michigan, Outpatient Clinics, Hospital, Pilot Projects, Remission Induction, Severity of Illness Index, Therapies, Investigational, Donor Selection, Young Adult, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.